Lobbying client
MYADERM
Producer of pharmacist-formulated, transdermal Cannabidiol (CBD) pain creams and topical C
Filings
16
Filed by
1
Reported in-house
—
Reported by firms
$100,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2019 to 2022
Filings
4 filings for 2022, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Termination (No Activity) 4th Quarter 2022
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2022
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2022
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2022
|
BUCHANAN INGERSOLL & ROONEY PC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| BUCHANAN INGERSOLL & ROONEY PC | 15 | $100,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 6 |
| Medical/Disease Research/Clinical Labs | MED | 6 |
| Pharmacy | PHA | 6 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.